Compound information
- Natural Products
- ZC890047
- Molecular Formula
- C16H19ClN2O3
- Molecular Weight
- 322.108420148 g/mol
- Structure
-
- IUPAC Name
- (1R,2S)-2-[4-(5-chloro-2-methyl-phenyl)piperazine-1-carbonyl]cyclopropanecarboxylic acid
- InChI
- InChI=1S/C16H19ClN2O3/c1-10-2-3-11(17)8-14(10)18-4-6-19(7-5-18)15(20)12-9-13(12)16(21)22/h2-3,8,12-13H,4-7,9H2,1H3,(H,21,22)/t12-,13+/m0/s1
- InChI Key
- VCKBZBBAHJLSJZ-QWHCGFSZSA-N
- SMILES
- Cc1ccc(Cl)cc1N1CCN(C(=O)[C@H]2C[C@H]2C(=O)O)CC1
- Source
- ZINC000003135709
Warheads
- Cyclopropane
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 22 | Ring Count | 3 |
| Heteroatom Count | 6 | Rotatable Bond Count | 3 |
| Hydrogen Bond Acceptor Count | 3 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 60.85 Å2 | LogP | 2.062 |
| LogS | -2.825 | LogD | 1.714 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.006 | Pgp substrate | 0.071 |
| HIA | 0.964 | F20 % | 0.993 |
| F30 % | 0.974 | Caco-2 | -5.094 |
| MDCK | -5.027 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.626 | PPB | 93.236 |
| VD | 0.694 | Fu | 1.407 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.001 | CYP1A2 substrate | 0.548 |
| CYP2A6 substrate | 0.48 | CYP2B6 substrate | 0.581 |
| CYP2C19 inhibitor | 0.075 | CYP2C19 substrate | 0.776 |
| CYP2C8 substrate | 0.602 | CYP2C9 inhibitor | 0.144 |
| CYP2C9 substrate | 1.0 | CYP2D6 inhibitor | 0.082 |
| CYP2D6 substrate | 0.428 | CYP2E1 substrate | 0.503 |
| CYP3A4 inhibitor | 0.027 | CYP3A4 substrate | 0.997 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.49 | CL | 0.712 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.1 | Hepatotoxicity | 0.996 |
| Mutagenicity | 0.004 | Rat Oral Acute Toxicity | 0.534 |
| FDAMDD | 0.615 | Skin Sensitization | 0.053 |
| Carcinogenicity | 0.008 | Eye Corrosion | 0.056 |
| Eye Irritation | 0.703 | Respiratory Toxicity | 0.086 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | -0.496 | IGC50 | 1.706 |
| LC50FM | -1.304 | LC50DM | 2.549 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.611 | NR-AR-LBD | 0.398 |
| NR-AhR | 0.181 | NR-Aromatase | 0.03 |
| NR-ER | 0.435 | NR-ER-LBD | 0.358 |
| NR-PPAR-gamma | 0.432 | SR-ARE | 0.234 |
| SR-ATAD5 | 0.278 | SR-HSE | 0.056 |
| SR-MMP | 0.008 | SR-p53 | 0.044 |
Similar covalent drugs
No similar covalent drugs found for this compound.